Opthea treats first patient in Phase 3 nAMD trial The first patient in the Phase 3 clinical trial of a Melbourne-based drug company’s novel therapy for neovascular age-related macular degeneration (nAMD) has been treated in the US.Read More rhiannon bowmanMarch 22, 2021, 10:11 amMarch 24, 2021
